HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seltzer, M. A. Articles by Barrio, J. R. Search for Related Content PubMed PubMed Citation Articles by Seltzer, M. A. Articles by Barrio, J. R.

Radiation Dose Estimates in Humans for ¹¹C-Acetate Whole-Body PET

¹ Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, University of California at Los Angeles School of Medicine, Los Angeles, California
² CDE Dosimetry Services, Knoxville, Tennessee

¹¹C-Acetate is currently being investigated as a new tracer for imaging neoplasms, most notably prostate cancer and its metastases. Previously reported dose estimates for ¹¹C-acetate prepared by the Oak Ridge Institute for Science and Education (ORISE) were based on a simple 3-compartment model in which all activity not measured in blood or excretion via breath was assumed to reside in the heart. Because all organs are involved in acetate metabolism to some extent, these estimates might overestimate heart and underestimate other organ dosimetry. Dynamic whole-body ¹¹C-acetate PET was therefore performed on 6 healthy human volunteers. Measured dose estimates for all target organs were compared with the existing ORISE values. Methods: After transmission scanning had been performed for measured attenuation, 525 MBq of ¹¹C-acetate were injected intravenously, and 5 sequential whole-body emission scans were obtained from the head to mid thighs. Regions of interest were drawn to encompass the entire activity in all visible organs at each time point. Time-activity data were fit in a least-squares sense to obtain residence times. Absorbed dose estimates were determined using MIRDOSE3.1 software. Results: The effective dose was 0.0049 mSv/MBq. The organs receiving the highest absorbed doses were the pancreas (0.017 mGy/MBq), bowel (0.011 mGy/MBq), kidneys (0.0092 mGy/MBq), and spleen (0.0092 mGy/MBq). No urinary excretion of tracer was measurable. Conclusion: Using these new estimates for ¹¹C-acetate dosimetry, the maximum injected activity under Radioactive Drug Research Committee limits can be raised up to 5-fold over the limit imposed by the previous ORISE estimates. A higher injected activity would improve counting statistics and, it is hoped, overall image quality and tumor detection with whole-body ¹¹C-acetate PET.

Key Words: ¹¹C-acetate • dosimetry • PET

Related articles in JNM:

This Month in JNM

JNM 2004 45: 13A-14A. [Full Text]  

This article has been cited by other articles:

				J. R. Virta, T. Tolvanen, K. Nagren, A. Bruck, A. Roivainen, and J. O. Rinne 1-11C-Methyl-4-Piperidinyl-N-Butyrate Radiation Dosimetry in Humans by Dynamic Organ-Specific Evaluation J. Nucl. Med., March 1, 2008; 49(3): 347 - 353. [Abstract] [Full Text] [PDF]

				C. Schiepers, C. K. Hoh, J. Nuyts, M. Seltzer, C. Wu, S.-C. Huang, and M. Dahlbom 1-11C-Acetate Kinetics of Prostate Cancer J. Nucl. Med., February 1, 2008; 49(2): 206 - 215. [Abstract] [Full Text] [PDF]

				V. L. Cropley, M. Fujita, J. L. Musachio, J. Hong, S. Ghose, J. Sangare, P. J. Nathan, V. W. Pike, and R. B. Innis Whole-Body Biodistribution and Estimation of Radiation-Absorbed Doses of the Dopamine D1 Receptor Radioligand 11C-NNC 112 in Humans J. Nucl. Med., January 1, 2006; 47(1): 100 - 104. [Abstract] [Full Text] [PDF]